Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: A proposed management algorithm

Kin Pan Au, Kenneth Siu Ho Chok

Abstract

A large number of liver transplants have been performed for hepatocellular carcinoma (HCC), and recurrence is increasingly encountered. The recurrence of HCC after liver transplantation is notoriously difficult to manage. We hereby propose multi-disciplinary management with a systematic approach. The patient is jointly managed by the transplant surgeon, physician, oncologist and radiologist. Immunosuppressants should be tapered to the lowest effective dose to protect against rejection. The combination of a mammalian target of rapamycin inhibitor with a reduced calcineurin inhibitor could be considered with close monitoring of graft function and toxicity. Comprehensive staging can be performed by dual-tracer positron emission tomography-computed tomography or the combination of contrast computed tomography and a bone scan. In patients with disseminated recurrence, sorafenib confers survival benefits but is associated with significant drug toxicity. Oligo-recurrence encompasses recurrent disease that is limited in number and location so that loco-regional treatments convey disease control and survival benefits. Intra-hepatic recurrence can be managed with graft resection, but significant operative morbidity is expected. Radiofrequency ablation and stereotactic body radiation therapy (SBRT) are effective alternative strategies. In patients with more advanced hepatic disease, regional treatment with trans-arterial chemoembolization or intra-arterial Yttrium-90 can be considered. For patients with extra-hepatic oligo-recurrence, loco-regional treatment can be considered if practical. Patients with more than one site of recurrence are not always contraindicated for curative treatments. Surgical resection is effective for patients with pulmonary oligo-recurrence, but adequate lung function is a pre-
INTRODUCTION

Despite stringent selection criteria, recurrence occurs in 6%-18% of patients transplanted for hepatocellular carcinoma (HCC)[1-4]. Since the implementation of the Model for End-Stage Liver Disease (MELD) system, patients waitlisted for HCC have been given increased priority for cadaveric grafts[5]. More liver transplants have been performed for HCC, and recurrence is more frequently encountered[6]. The recurrence of HCC after liver transplantation is notoriously difficult to manage. Experience is limited in the literature, and there is considerable debate concerning various systemic and local treatments. The objective of the present narrative review is to summarize the current available literature and propose a management algorithm for recurrence after liver transplantation.

A literature search was performed on PubMed (United States National Library of Medicine, National Institutes of Health, United States) for relevant English articles with a combination of keywords: “liver transplantation” with “hepatocellular carcinoma recurrence” or “HCC recurrence” and/or “immunosuppression” and/or “targeted therapy” and/or “immunotherapy” and/or “resection” and/or “ablation” and/or “stereotactic body radiotherapy” or “SBRT”. The references of the selected papers were reviewed for additional relevant articles.

UNIQUE PERSPECTIVES OF POST-TRANSPANT RECURRENCE

Systemic disease

After liver transplantation, any recurrence is, by definition, metastasis from the native liver. The culprit is either the presence of undiagnosed distant metastasis before transplantation or spillage of tumour cells during transplantation. Even an isolated recurrence implicates solitary metastasis and represents a local phenomenon of the systemic event, which highlights the importance of systemic therapy and the input of oncology as a critical component of the therapeutic strategy.

Immuno-compromised state

Immunity is the primary defence against cancer[7]. The adaptive immune system recognizes and eliminates tumour cells based on their expression of tumour-specific antigens[8]. Concomitant immunity, the immune response induced by the primary tumour inhibits the growth of secondaries[9]. However, after liver transplantation, concomitant immunity is suppressed pharmacologically. Any microscopic tumour in vitro can progress without immune surveillance. It was observed that post-transplant HCC recurrence progresses significantly faster than in patients treated with hepatic resection[10].

Calcineurin inhibitors, e.g., tacrolimus and cyclosporine, form the cornerstones of maintenance immunosuppression in liver transplantation. In addition to host immune suppression, they promote tumour progression via non-immune-mediated pathways related to augmented transforming growth factor expression[11,12]. From a retrospective series of 70 HCC patients treated with liver transplantation, quantified cyclosporine exposure was identified as an independent risk factor for HCC recurrence[13]. Subsequently, Vivarelli et al[14] confirmed that high tacrolimus exposure independently predicted HCC recurrence. Immunosuppressive therapy affects the course of tumours in transplant patients and must be fully addressed in the comprehensive management of a recurrence.

Immuno-maintenance phase of the transplant

Throughout the course of treatment, the liver graft must be maintained. Reduction of immunosuppression increases the risk of graft rejection. Medical therapies potentially affect liver function. The use of immunotherapy is particularly concerned with immune-mediated graft injury. While formulating the treatment strategy, the benefits of the treatment must be balanced...
with the potential toxicities towards the liver graft.

**PROPOSED TREATMENT ALGORITHM**

The patient is jointly managed by the transplant surgeon, physician, oncologist and radiologist under a multidisciplinary approach.

**IMMUNOSUPPRESSION**

Whenever a recurrence is diagnosed, the immunosuppressant should be reviewed. Considering that immune failure contributes to cancer progression, immunosuppression should be tapered to the lowest effective dose protecting against rejection. Moreover, the regimen of immunosuppression warrants reconsideration.

**Mammalian target of rapamycin inhibitor**

Mammalian target of rapamycin (mTOR) is a protein involved in a signalling pathway that controls cellular growth and proliferation\[15\]. Rapamycin, more commonly known as sirolimus, inhibits the mTOR pathway to restrain regulatory T-cell proliferation\[16\]. Apart from immune modulation, mTOR is also involved in HCC pathogenesis and is associated with poor tumour biology\[17-19\]. Sirolimus has been investigated in a phase II trial showing promising efficacy against advanced HCC\[20\]. With the theoretical advantage over tumour control, sirolimus has been extensively investigated as immunosuppression therapy for patients engrafted for HCC\[21-27\] (Table 1).

The highest level of evidence came from a prospective trial conducted by Geissler et al\[28\], where 525 patients were randomized to receive either a sirolimus-based or an mTOR inhibitor-free regimen. In the study group, sirolimus was incorporated 4–6 wk after transplantation, with or without a concomitant calcineurin inhibitor. The overall and recurrence free survival rates were improved up to 5 years (overall survival: 79.4% vs 70.3%; \(P = 0.048\)) and 3 years (disease-free survival: 80.6% vs 72.3%; \(P = 0.0499\)). The proportion of patients with acute rejection appeared to be higher in the sirolimus group (23.4% vs 17.0%, respectively; \(P = 0.07\)), but the difference did not reach statistical significance. The results were in concordance with an updated meta-analysis that demonstrated a survival benefit in patients receiving sirolimus-based immunosuppression therapy \((\text{OR} = 1.68; \text{CI} = 1.21-2.33)\)\[29\]. From the pooled results of 11 studies, the risk of graft rejection or hepatic artery thrombosis was not increased. Sirolimus was generally well tolerated. In a small proportion of patients (0-8.3%), sirolimus was discontinued for drug toxicity, mostly due to oral ulcers\[29\].

Everolimus is a derivative of sirolimus with a shorter elimination half-life (30 h vs 60 h) and a quicker time to steady state (4 d vs 6 d)\[29,30\]. The clinical advantage is easier dose adjustment. Everolimus received evaluation in a phase III trial for its role in advanced primary HCC that progressed despite sorafenib therapy\[31\]. However, no further survival benefit was observed upon switching to everolimus (overall survival: 7.6 mo vs 7.3 mo). Everolimus has been evaluated in prospective trials for its efficacy in liver transplantation, although they were not focused on oncological outcomes. In a prospective multicentre study, everolimus with a reduced dose of tacrolimus was associated with better preserved renal function (estimated glomerular filtration rate decline over 36 mo: 7.0 mL/min/1.73 m\(^2\) vs 15.5 mL/min/1.73 m\(^2\); \(P = 0.005\)) compared with the standard dose of tacrolimus\[32\]. A similar regimen was studied in another prospective trial with a composite primary endpoint comprising rejection and graft loss\[33\]. Notably, in patients transplanted for HCC, recurrence was only observed in the control arm with a standard dose of tacrolimus (5/62 vs 0/62) after 12 mo of follow up. A direct comparison between everolimus and sirolimus was made in a meta-analysis\[34\]. Patients on everolimus had significantly fewer recurrences than those on sirolimus or calcineurin inhibitors (4.1% vs 10.5% vs 13.8%, respectively; \(P < 0.05\)). However, everolimus-treated recipients had a shorter follow-up time (13 mo vs 30 mo vs 43.2 mo, respectively) and fewer advanced tumours (HCC within Milan criteria: 84% vs 60.5% vs 74%, respectively; \(P < 0.05\)). The study did not compare survival, and no definite conclusions were drawn.

The data on mTOR inhibitor therapy for established recurrence after liver transplantation remain scarce. However, a combination of either sirolimus or everolimus with reduced-dose tacrolimus has been proven to be safe and effective in reducing recurrence\[24,28,33\]. There is inadequate evidence to recommend the optimal serum level of tacrolimus in this combination. In our experience, a sub-therapeutic level of tacrolimus might suffice. From Geissler’s prospective trial it appears that Sirolimus monotherapy might be adequate for some patients\[21\]. From a registry database comprising 2491 patients transplanted for HCC, sirolimus was the only maintenance immunosuppressant affecting survival (5-year survival: 83.1% vs 68.7%, \(P < 0.05\))\[27\]. Based on these findings, it appears sensible to incorporate an mTOR inhibitor with a reduced calcineurin inhibitor upon the diagnosis of recurrence. Overall, immunosuppression should be individualized and tapered to spare the remaining anti-tumour immunity. Patients should be closely monitored for liver function throughout the course of cancer treatment.

**STAGING**

Because post-transplant recurrence is essentially metastatic disease, complete staging is essential to guide subsequent management. Dual tracer positron emission tomography-computed tomography (PET-CT) has been validated for pre-transplant staging for HCC patients\[35\]. During the examination, a whole-body survey, both functional and structural, is performed for
comprehensive staging. The two radioisotopes, namely C11-acetate and fludeoxyglucose (FDG), complement each other. C11-acetate is sensitive for well-differentiated HCC, but tumours with more unfavourable biology may have a predilection towards FDG[36]. Combining two tracers enhances sensitivity to detect occult metastasis. Dual tracer PET-CT is especially advantageous over computed tomography (CT) to diagnose bone metastasis (sensitivity 97% vs 72%, respectively; P < 0.05) and is not uncommon in patients with recurrence after liver transplantation[37].

Albeit effective, dual-tracer PET-CT may not be widely available. When contrast CT is performed as an alternative, it is better coupled with a skeletal survey using bone scan. Bone is the third most common site of recurrence after the lung and liver, affecting 20% of patients with recurrence[38]. The objective of radiological staging is to determine whether the recurrence is disseminated or limited, i.e., oligo-recurrence. While disseminated recurrence is managed primarily with systemic therapy, limited recurrence may be better controlled with additional loco-regional treatment. It has been observed that R0 resection conferred a survival benefit in selected candidates with isolated and resectable metastasis[39].

**DISSEMINATED RECURRENCE**

Disseminated recurrence is primarily managed with systemic treatment with the intention to prolong survival rather than to pursue cure.

**Targeted therapy**

Sorafenib is a multi-tyrosine kinase inhibitor with activity against vascular endothelial growth factor-2 and -3, platelet-derived growth factor receptor and Ras ligand[40]. It inhibits tumour signalling and angiogenesis pathways involved in HCC pathogenesis. In a randomised controlled trial, sorafenib was shown to prolong the median survival of patients with advanced HCC for 3 mo (10.7 mo vs 7.9 mo, P < 0.001)[41]. The major drawback was a poorly tolerated side effects profile. Hand-foot skin reaction and gastrointestinal disturbances were reported in 21% and 39% of the patients, respectively. Although mostly graded as 1 and 2 in severity, drug-related adverse events have led to discontinuation of sorafenib in 29% of the patients.

The efficacy of sorafenib in post-transplant HCC recurrence has been studied in numerous retrospective series, mostly in combination with an mTOR inhibitor (Table 2)[42-52]. Sorafenib and mTOR inhibition had synergistic effects on tumour growth in xenograft mice[53]. Ras blockade silenced the feedback signalling of mTOR inhibition, leading to upregulation of its anti-tumour activity[54]. A retrospective cohort reported by DeAngelis et al[45] provided insights into the use of sorafenib in patients with advanced recurrence. The outcomes of 15 patients treated with sorafenib were compared with those of 24 patients receiving best supportive care. Sorafenib was stared at 400 mg twice daily. More patients in the sorafenib group received an mTOR inhibitor due to the time effect, but the difference did not reach statistical significance (46.7% vs 16.7%, P = 0.13). Sorafenib conferred disease control (partial response or stable disease) in 11 of the 15 patients (73.4%), translating into a survival benefit (median OS: 41.4 mo vs 19.1 mo; P = 0.013). Notably, there was a high proportion of patients requiring dose reduction (53.3%) or discontinuation of treatment (13.3%) due to drug toxicity.

Gomez-Martín et al[50] addressed the safety of combining sorafenib with an mTOR inhibitor in a post-transplant setting. In the multicentre cohort consisting of 31 patients with recurrent HCC, the immunosuppression was shifted to mTOR inhibitor therapy with initiation of sorafenib as systemic treatment. Most toxicities were grade 1 or 2. However, 2 episodes of gastric bleeding and 1 episode of cerebral haemorrhage were reported. The gastric bleedings were diffuse mucosal oozing unrelated to portal hypertension or ulcer disease. Thus, sorafenib appears to be effective to prolong

### Table 1 Mammalian target of rapamycin inhibitors for patients engrafted for hepatocellular carcinoma

| Study                          | SRL/non-SRL | 5-year OS (%) | 5-year DFS (%) | HAT (%) | ACR (%) | Discontinuation for toxicity (%) |
|--------------------------------|-------------|---------------|----------------|---------|---------|---------------------------------|
| Prospective controlled trial   |             |               |                |         |         |                                 |
| Geissler et al(23), 2016        | 261/264     | 79.4/70.3†    | 72.6/68.4      | -       | 23.4/17.0 | -                              |
| Meta-analysis                   |             |               |                |         |         |                                 |
| Liang et al(27), 2012           | 332/2615    | OR: 2.47      | 1 yr: OR 2.41† | OR: 1.32 | -       | -                              |
| Zhang et al(28), 2018           | 7695        | OR: 1.68      | 1 yr: OR 2.13† | -       | -       | -                              |
| Case-control                    |             |               |                |         |         |                                 |
| Vivarelli et al(29), 2010      | 31/31       | -             | 3 yr 86/56†    | 0/0     | 3.2/3.2 | -                              |
| Retrospective cohort            |             |               |                |         |         |                                 |
| Zimmerman et al(30), 2007      | 45/52       | 80/62         | 78.8/54        | 2.4/1.9 | 20/19.6 | -                              |
| Zhou et al(31), 2008           | 27/46       | 19.8 ± 1.2/16.0 ± 1.4† | 17.3 ± 1.4/15.9 ± 1.6† | 0/0 | 30.4/19.6 | 8.3    |
| Chinnakotla et al(32), 2009     | 121/106     | 80/50†        | -              | 1.9/2   | 62.8/54.7 | 0      |
| Tono et al(33), 2010           | 109/2382    | 83.1/68.7†    | -              | -       | -       | -                              |

1All tumours were beyond Milan criteria; 2Median survival in months; 3Statistically significant. SRL: Sirolimus; OS: Overall survival; DFS: Disease-free survival; HAT: Hepatic artery thrombosis; ACR: Acute cellular rejection.
survival after recurrence but at the cost of significant toxicity. Combination treatment with an mTOR inhibitor should be avoided in patients with potential bleeding complications.

### Immunotherapy

Immunotherapy directs the host immunity towards the tumour\(^{55}\). The physiological immune response is regulated by immune checkpoints\(^{56}\). Immunotherapy consists of antibodies directed against these immune checkpoints on the T-cell surface to prompt reactions against tumour antigens. Examples include ipilimumab that targets cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and nivolumab and pembrolizumab that target programmed cell death protein 1 (PD-1). Nivolumab has been validated in a large phase II trial for its safety and efficacy against primary HCC\(^{57}\). Nivolumab 3 mg/kg was given every 2 wk to 214 patients with advanced HCC. Disease control was achieved in 64% of all patients, including 61% of patients who had previously failed sorafenib treatment. The overall survival was 83% at 6 mo. There was a favourable side effect profile compared with that of sorafenib. Only 2%-4% of patients discontinued nivolumab due to drug toxicity.

However, immune checkpoint modulation of cell-mediated immunity is implicated in transplant organ tolerance\(^{(58,59)}\). Downregulation of these pathways may inadvertently lead to transplant rejection\(^{60}\). In fact, clinical trials for immune checkpoint inhibitors often exclude solid organ transplant recipients due to the fear of graft injury\(^{56,62}\). Current experience in immunotherapy after liver transplantation is confined to case reports and small series\(^{(53-66)}\) (Table 3). Limited survival (0.3 mo to 3 mo) was observed among the 10 patients treated with anti-PD-1. The salvage nature of immunotherapy must be considered while interpreting the results. Most patients had developed disease progression with sorafenib. Moreover, the clinical decision to employ immunotherapy for transplant patients is usually much delayed until treatment failure is evident. Although the therapeutic effect is considered rapid for immunotherapy, a 3-m interval is usually necessary before the treatment response can be evaluated\(^{67}\). In the reports, the rather limited survival interval after immunotherapy might not allow the efficacy of immunotherapy to be assessed.

Acute rejection occurred in 3 of the 10 reported cases receiving anti-PD-1 treatment. Although a limited number of events precludes risk factor analysis, a hypothesis could be proposed. Two patients with rejection were relatively young, aged 14 and 20 years, respectively. A young age is a recognized risk factor for acute rejection after liver transplantation, and more aggressive immunosuppression is usually employed\(^{67}\). A long duration after transplantation is usually protective of acute rejection. However, the trend is not obvious from this series of observations. Practically, most recurrence occurs early after transplantation as well.

The differential effect of PD-1 and CTLA-4 blockade on rejection may also have implications\(^{68}\). Among the 5 reported liver transplant patients treated with immunotherapy for melanoma, rejection was observed only in patients receiving a PD-1 inhibitor\(^{56,69,70}\) (Table 3). These clinical observations concurred with the findings from in vitro studies. Using a murine model it was demonstrated that the PD-1 pathway may play a stronger role in allograft tolerance than CTLA-4 and that PD-1 blockade could be associated with a higher risk of transplant rejection\(^{72}\). However, the effect of CTLA-4 blockade on HCC control has not been systematically investigated. The role of immunotherapy in treating HCC recurrence after liver transplantation remains largely unknown. The potential efficacy should not be overlooked but has to be balanced with its safety\(^{73}\). Further study in a large patient cohort is warranted to elucidate optimal patient selection.

---

### Table 2 Sorafenib for recurrent hepatocellular carcinoma after liver transplantation

| Meta-analysis | No. (SFN/ BSC) | Duration after LT (mo) | mTOR Inhibitor (yes/no) | Response rate (% complete/partial/stable) | Median OS (mo) | Time to progression (mo) | Drug toxicity leading to dose reduction Discontinuation (% patient) |
|---------------|----------------|-----------------------|-------------------------|------------------------------------------|----------------|------------------------|---------------------------------------------------------------|
| Mancuso et al\(^{43}\), 2015 | 113 | 13.6 | - | 0/4.8/44.4 | 10.5 | 5.6 | 42.8/31.9 |
| Retrospective cohort | | | | | | | |
| Sposito et al\(^{44}\), 2013 | 15/24 | 38.1/15.7\(^{7}\) | 7/8 | - | 21.3/11.8\(^{8}\) | 8.8/10.2 | 53.3 | 4.1 |
| De’Angelis et al\(^{45}\), 2016 | 15/18 | 18 | 7/8 | 0/26.6/46.8 | 41.4/19.1\(^{1}\) | - | 53.3 | 13.3 |
| Pinero et al\(^{46}\), 2016 | 10/10 | - | 7/3 | - | 20/12.5 | 5/3\(^{3}\) | 90 | 20 |
| Case series | | | | | | | |
| Yoon et al\(^{47}\), 2010 | 13 | 12.3 | 1/12 | 0/3.0/46 | 5.4 | 2.9 | 30.7 | 0 |
| Kim et al\(^{48}\), 2010 | 9 | 12.4 | 7/2 | 11/0/44 | 1.\(^{1}\) | - | - | 0 |
| Vitale et al\(^{49}\), 2012 | 10 | 7 | 10/0 | 0/20/60 | 18 | 8 | 40 | 30 |
| Gomez-Martin et al\(^{50}\), 2012 | 31 | 22.6 | 31/0 | 0/3.8/50 | 19.3 | 6.77 | 25.8 | - |
| Weimann et al\(^{51}\), 2012 | 11 | 37.5 | 9/2 | 0/0/36 | 20.1 | 4.1 | 73 | 18 |
| Sotiropoulos et al\(^{52}\), 2013 | 14 | 8 | 14/0 | - | 25 | - | 33 | 17 |
| Zavaglia et al\(^{53}\), 2013 | 11 | 12 | 7/4 | 0/18/9 | 5 | 17 | 90 | - |

\(^{1}\)Median survival not reached; \(^{2}\)Statistically significant. SFN: Sorafenib; BSC: Best supportive care; LT: Liver transplant; mTOR: Mammalian target of rapamycin; OS: Overall survival.
MANAGEMENT OF OLIGO-RECURRENCE

Historically, distant recurrence is considered to be terminal. Post-transplant recurrence is, by definition, distant metastasis from the native liver and has been managed with palliative intent. However, the new notions of oligo-recurrence have led to a paradigm shift in the management of cancer recurrence or metastasis. First introduced by Hellman and Weichselbaum in 1995, the term described recurrent disease that was limited in number and location so that loco-regional treatments improved survival[74]. Oligo-recurrence represents a therapeutic opportunity that allows the patient to be treated with a curative strategy. Due to the improvement in systemic therapy, a durable cure is no longer a remote possibility in patients with limited disease. The concept has gained substantial popularity, and oligo-recurrences have been managed with a combination of systemic and loco-regional treatments with promising results[75]. A stringent definition for oligo-recurrence in terms of the number, size, or distribution of tumour is impractical. A pragmatic view to the concept is a rational use of loco-regional therapy in patients for whom disease burden is limited.

Role of surgery
The results for surgical resection have been retrospectively reported for patients with intra-hepatic or extrahepatic oligo-recurrence (Table 4)[4,39,76-79]. Patients eligible for surgical treatment ranged from 25% to 50%. The lung and liver were common sites for resection (Table 4). Survival benefits have been consistently demonstrated in patients treated with surgery, with a median survival of 28 mo to 65 mo observed for patients receiving surgery, compared with 5 mo to 15 mo in those receiving systemic treatment only[4,39,76-79].

Selection bias was inevitable because surgical candidates were invariably patients with localized disease and a better prognosis. In the most recent series, patient selection was further refined with an additional criterion being the absence of progression while on systemic treatment[79]. The genuine benefit conveyed by surgery could be questioned because the selected patients had a limited disease burden and more favourable tumour biology. However, a prospective randomized trial is unlikely under the current setting to be given ethical concern. A matched retrospective comparison is also difficult due to the intrinsic differences between the patients with oligo- and disseminated recurrence.

Reviewing the current literature, long-term survival after post-transplant recurrence has been achieved with surgical resection. Across numerous reported series, surgical treatment remained an independent predictor of superior survival after recurrence[4,76,77,79]. Surgery is supported as the treatment of choice in patients with resectable recurrence, especially when the tumour

| Patient | Age | Ref. | Tumour | Agent | Years after LT | Immunosuppression | Prior sorafenib | Response | OS (mo) | Rejection |
|---------|-----|------|--------|-------|--------------|-------------------|---------------|----------|---------|----------|
| 1       | 41  | De Toni et al[63], 2017 | HCC | Nivolumab | 1 | Low dose tacrolimus | Yes | No | - | No |
| 2      | 20  | Friend et al[6], 2017 | HCC | Nivolumab | 4 | Sirolimus | - | 1 | Yes |
| 3      | 14  | Friend et al[6], 2017 | HCC | Nivolumab | 3 | Tacrolimus | - | 1 | Yes |
| 4      | 70  | Varkaris et al[68], 2017 | HCC | Pembrolizumab | 8 | Low dose tacrolimus | Yes | No | 3 | No |
| 5      | 57  | DeLeon et al[64], 2018 | HCC | Nivolumab | 2.7 | Tacrolimus | Yes | No | 1.2 | No |
| 6      | 56  | DeLeon et al[64], 2018 | HCC | Nivolumab | 7.8 | MMF/sirolimus | Yes | No | 1.1 | No |
| 7      | 35  | DeLeon et al[64], 2018 | HCC | Nivolumab | 3.7 | Tacrolimus | Yes | No | 1.3 | No |
| 8      | 64  | DeLeon et al[64], 2018 | HCC | Nivolumab | 1.2 | Tacrolimus | Yes | 2 | 0.3 | No |
| 9      | 68  | DeLeon et al[64], 2018 | HCC | Nivolumab | 1.1 | Sirolimus | Yes | - | 0.7 | Yes |
| 10     | 70  | Varkaris et al[68], 2017 | HCC | Pembrolizumab | 6 | Low dose tacrolimus | Yes | No | 3 | No |
| 11     | 59  | Ranganath et al[62], 2015 | Melanoma | Ipilimumab | 8 | Tacrolimus | - | - | - | No |
| 12     | 67  | Morales et al[67], 2015 | Melanoma | Ipilimumab | 8 | Sirolimus | - | - | - | No |
| 13     | 55  | DeLeon et al[64], 2018 | Melanoma | Pembrolizumab | 5.5 | MMF/everolimus | - | - | - | No |
| 14     | 63  | DeLeon et al[64], 2018 | Melanoma | Pembrolizumab | 3.1 | MMF/prednisolone | - | - | - | Yes |
| 15     | 62  | Kuo et al[63], 2018 | Melanoma | Ipilimumab and pembrolizumab | 6 | Sirolimus | - | - | - | Yes |

1Fibrolamella hepatocellular carcinoma; 2Multiorgan failure, unrelated to immunotherapy. HCC: Hepatocellular carcinoma; LT: Liver transplant; OS: Overall survival.
Liver (n = 2), adrenal (n = 2), abdomen (n = 2), chest wall (n = 1)¹.
Liver (n = 2, lung (n = 2), others (n = 3)
Liver (n = 2, lung (n = 2), adrenal (n = 2), abdominal lymph node (n = 2)
Liver (n = 8), bone (n = 6), intra-abdominal (n = 4), liver (n = 3), brain (n = 2)
Liver (n = 2), lung (n = 2, 7), adrenal (n = 2), chest wall (n = 1)¹.
Liver (n = 2), lung (n = 2), others (n = 3)
Liver (n = 2, lung (n = 2), adrenal (n = 2), abdomen (n = 2), chest wall (n = 1)¹.
Liver (n = 2), lung (n = 2), others (n = 3)
Liver (n = 2, lung (n = 2), adrenal (n = 2), abdominal lymph node (n = 2)
Liver (n = 2), lung (n = 2), others (n = 3)
Liver (n = 2), lung (n = 2), abdomen (n = 2), chest wall (n = 1)¹.
Liver (n = 2), lung (n = 2), others (n = 3)
Liver (n = 2, lung (n = 2), adrenal (n = 2), abdomen (n = 2), chest wall (n = 1)¹.
Liver (n = 2, lung (n = 2), others (n = 3)
Liver (n = 2, lung (n = 2), adrenal (n = 2), abdomen (n = 2), chest wall (n = 1)¹.
Liver (n = 2, lung (n = 2), others (n = 3)
Liver (n = 2, lung (n = 2), adrenal (n = 2), abdomen (n = 2), chest wall (n = 1)¹.
Liver (n = 2, lung (n = 2), others (n = 3)
Liver (n = 2, lung (n = 2), adrenal (n = 2), abdomen (n = 2), chest wall (n = 1)¹.
Liver (n = 2, lung (n = 2), others (n = 3)
Liver (n = 2, lung (n = 2), adrenal (n = 2), abdomen (n = 2), chest wall (n = 1)¹.
Liver (n = 2, lung (n = 2), others (n = 3)
Liver (n = 2, lung (n = 2), adrenal (n = 2), abdomen (n = 2), chest wall (n = 1)¹.
Liver (n = 2, lung (n = 2), others (n = 3)
Liver (n = 2, lung (n = 2), adrenal (n = 2), abdomen (n = 2), chest wall (n = 1)¹.
Liver (n = 2, lung (n = 2), others (n = 3)
Liver (n = 2, lung (n = 2), adrenal (n = 2), abdomen (n = 2), chest wall (n = 1)¹.
Liver (n = 2, lung (n = 2), others (n = 3)
Liver (n = 2, lung (n = 2), adrenal (n = 2), abdomen (n = 2), chest wall (n = 1)¹.
Liver (n = 2, lung (n = 2), others (n = 3)
Liver (n = 2, lung (n = 2), adrenal (n = 2), abdomen (n = 2), chest wall (n = 1)¹.
Liver (n = 2, lung (n = 2), others (n = 3)
Liver (n = 2, lung (n = 2), adrenal (n = 2), abdomen (n = 2), chest wall (n = 1)¹.
Liver (n = 2, lung (n = 2), others (n = 3)
Liver (n = 2, lung (n = 2), adrenal (n = 2), abdomen (n = 2), chest wall (n = 1)¹.
Liver (n = 2, lung (n = 2), others (n = 3)
Liver (n = 2, lung (n = 2), adrenal (n = 2), abdomen (n = 2), chest wall (n = 1)¹.
Liver (n = 2, lung (n = 2), others (n = 3)
Liver (n = 2, lung (n = 2), adrenal (n = 2), abdomen (n = 2), chest wall (n = 1)¹.
Liver (n = 2, lung (n = 2), others (n = 3)
Liver (n = 2, lung (n = 2), adrenal (n = 2), abdomen (n = 2), chest wall (n = 1)¹.
Liver (n = 2, lung (n = 2), others (n = 3)
Liver (n = 2, lung (n = 2), adrenal (n = 2), abdomen (n = 2), chest wall (n = 1)¹.
Liver (n = 2, lung (n = 2), others (n = 3)
Liver (n = 2, lung (n = 2), adrenal (n = 2), abdomen (n = 2), chest wall (n = 1)¹.
Liver (n = 2, lung (n = 2), others (n = 3)
Liver (n = 2, lung (n = 2), adrenal (n = 2), abdomen (n = 2), chest wall (n = 1)¹.
Liver (n = 2, lung (n = 2), others (n = 3)
Liver (n = 2, lung (n = 2), adrenal (n = 2), abdomen (n = 2), chest wall (n = 1)¹.
Liver (n = 2, lung (n = 2), others (n = 3)
Liver (n = 2, lung (n = 2), adrenal (n = 2), abdomen (n = 2), chest wall (n = 1)¹.
Liver (n = 2, lung (n = 2), others (n = 3)
Liver (n = 2, lung (n = 2), adrenal (n = 2), abdomen (n = 2), chest wall (n = 1)¹.
Liver (n = 2, lung (n = 2), others (n = 3)
Liver (n = 2, lung (n = 2), adrenal (n = 2), abdomen (n = 2), chest wall (n = 1)¹.
Liver (n = 2, lung (n = 2), others (n = 3)
Liver (n = 2, lung (n = 2), adrenal (n = 2), abdomen (n = 2), chest wall (n = 1)¹.
Liver (n = 2, lung (n = 2), others (n = 3)
Liver (n = 2, lung (n = 2), adrenal (n = 2), abdomen (n = 2), chest wall (n = 1)¹.
reported series, 15 patients were treated with surgery while 11 received RFA. The author reported similar 3-year (51% vs 51%, P = 0.88) and 5-year (35% vs 28%, P = 0.88) overall survivals in two groups. However, both hepatic and extra-hepatic recurrences were included, and the results represented the outcomes of heterogeneous procedures. Morbidity and mortality after graft resection were not reported.

**Stereotactic body radiation therapy**

Stereotactic body radiation therapy (SBRT) is a precise method of delivering ablative radiation by tomographic modulation. Intense and focused doses of radiation are given in a few or single fractions. SBRT for post-transplant HCC recurrence has several theoretical advantages. The radiation beam is focused on the tumour, sparing the adjacent normal liver parenchyma. A higher dose of radiation is delivered while the risk of collateral damage is minimized. Moreover, SBRT is delivered over fewer treatment days than the 10-20 d for conventional radiotherapy, during which systemic therapy is usually deferred. SBRT is usually completed in 1-5 fractions, allowing systemic treatment to be commenced early.

Moreover, it is now established in pre-clinical models that stereotactic radiation upregulates anti-tumour immunity. High-dose radiation stimulate antigen-presenting cells, leading to the activation and proliferation of tumour-specific cytotoxic T cells. The abscopal response (from "ab scopus", meaning away from target) denotes this systemic effect leading to the regression of metastatic lesions outside the irradiation field. Interestingly, abscopal effect is synergistically enhanced when combined with immunotherapy-mediated PD-1 blockade, which potentially confers a further clinical advantage to SBRT for recurrent HCC because the role of systemic therapy is crucial.

SBRT has been investigated in several prospective studies for primary HCC. In these series, the tumour size ranged from 2 cm to 7 cm. At 2 years after ablation, local control was achieved in 80% to 95% of patients. The figure compares favourably with that reported for RFA of small tumours. In contrast to RFA, vascular invasion is not a contraindication. In direct retrospective comparison, local control was found to be superior in the SBRT group for tumours more than 2 cm in size (HR: 3.35; P = 0.025). Grade III or above morbidity was similar (SBRT vs RFA: 5% vs 11%; P = 0.31). While RFA loses efficacy with increasing tumour size, SBRT seems to be as effective when treating larger tumours. To date, the role of SBRT for post-transplant HCC recurrence has yet to be systematically evaluated. While systemic control is of utmost importance, the potential of the SBRT and immunotherapy combination should be conscientiously explored.

**Trans-arterial chemoembolization**

In patients with multifocal intra-hepatic recurrence, trans-arterial chemoembolization (TACE) offers the opportunity of regional control. Ko et al. first reported the results of TACE for recurrent HCC after liver transplantation with 1- and 3-year survival rates of 47.9% and 6.0%, respectively. However, in their series, 64.3% of patients developed concomitant extra-hepatic metastasis, which could have affected the oncological outcome as well. Zhou et al. prospectively compared TACE versus systemic therapy in patients with unresectable intra-hepatic recurrence. Survival benefits were achieved in the TACE arm (P = 0.013), indicating that regional control could have contributed to the improvement in overall survival. Notably, both studies reported no major morbidity after graft liver TACE. In Zhou et al.’s series of 14 patients, no biliary complications were observed over a median follow up of 14.5 mo.

**Trans-arterial radioembolization**

Intra-arterial irradiation with Yttrium-90 (Y-90) microspheres has gained popularity in recent years to treat unresectable HCC. Injected through the feeding vessels, these microspheres emit high-dose radiation after entrapment at the pre-capillary level. In a large-scale longitudinal cohort comprising 291 patients, Y-90 achieved a 40%-60% response rate. The median survival was 17.2 mo in patients with Child’s A cirrhosis. In contrast to TACE, portal vein thrombosis is not a contraindication. Considering the potential synergistic effect of irradiation and immunotherapy, clinical studies are ongoing to investigate the benefit of combining Y-90 and anti-PD1 therapy for primary HCC. Their results will shed light on further applications concerning post-transplant HCC recurrence.
EXTRA-HEPATIC OLIGO-RECURRENCE

The lung is the most common site for extra-hepatic recurrence, followed by the bone\textsuperscript{[4,38,103]}. In the literature, the largest series of pulmonary metastatectomy after liver transplantation was reported by Hwang et al\textsuperscript{[104]}. Among 43 patients with lung recurrence, 23 were selected for surgery based on the feasibility of complete resection with sufficient pulmonary function after surgery. Patients were resected for up to 3 tumours, regardless of laterality. Over a mean follow up of 33 mo, 4 patients (17.4\%) remained disease-free. The resection group had a significantly greater 5-year survival rate (44.7\% vs 12.8\%; \( P = 0.017 \)). There was no operative mortality or morbidity. The results from this retrospective study indicate that pulmonary resection for oligo-recurrence is safe and offers the chance for long-term survival.

Five patients in the resection group had prior extra-pulmonary recurrence successfully treated with loco-regional treatments (3 intrahepatic recurrences ablated with RFA, 1 adrenal and 1 diaphragmatic recurrence excised). Among the 19 patients who developed recurrences after pulmonary resection, 13 received further loco-regional therapy (pulmonary and extra-pulmonary) to enhance disease control. From this series, the notion of oligo-recurrence management was well demonstrated.

When pulmonary metastatectomy is precluded by inadequate lung function, SBRT is considered an alternative\textsuperscript{[105]}. In a German multicentre cohort, 700 patients were treated with SBRT for inoperable pulmonary oligometastasis. The two-year local control and overall survival rates were reported as 82.1\% and 54.4\%, respectively. Grade 2 or higher pneumonitis occurred in 4.5\%-6.5\% of patients. SBRT has also been used to treat skeletal oligometastasis from visceral malignancies\textsuperscript{[106-109]}. The 1-year local control rates were 83\% and 91\% in patients with and without prior radiotherapy, respectively\textsuperscript{[109]}. Stereotactic irradiation was well tolerated with the most common toxicity reported as a transient pain flare\textsuperscript{[108]}. SBRT has been evaluated to treat skeletal metastasis from HCC with a local control rate up to 79\% to 88\%\textsuperscript{[110,111]}. With these promising results, the role of SBRT for skeletal oligo-recurrence after transplantation should be further explored.

CONCLUSION

To date, experience in managing post-transplant recurrence remains limited. Paucity of high level evidence renders a systematic review or meta-analysis difficult. We hereby propose a multi-disciplinary management algorithm with a systematic approach based on centre experience and best available evidence (Figure 1). The

---

**Figure 1  Multidisciplinary approach to manage post-transplant hepatocellular carcinoma recurrence.** HCC: Hepatocellular carcinoma; PET-CT: Positron emission tomography-computed tomography; SBRT: Stereotactic body radiation therapy.
patient is jointly managed by the transplant surgeon, physician, oncologist and radiologist. Following a diagnosis of recurrence, immunosuppression is reviewed. Immunosuppressants should be tapered to the lowest effective dose protecting against rejection. mTOR inhibitors are associated with anti-tumour effects and are potentially beneficial to tumour control. The combination of an mTOR inhibitor with a reduced calcineurin inhibitor can be considered with close monitoring of graft function and toxicity.

Comprehensive staging is mandatory due to the systemic disease nature. Dual-tracer PET-CT is an effective modality for staging. When contrast CT is used, it is better coupled with a bone scan. The essence of staging is to delineate the extent of disease. In patients presenting with disseminated recurrence, sorafenib may confer survival benefits but is associated with significant drug toxicity and is generally poorly tolerated. Dose reduction is frequently required. Patients at risk of bleeding complications should be avoided for the mTOR and sorafenib combination. In patients with poor tolerance to sorafenib, enrolment into a clinical trial may be beneficial. Disease progression is monitored biochemically with the serum level of AFP and radiologically with reassessment scans. Whenever disease progression is evident, the patients should be reviewed for the feasibility of loco-regional treatment. Additional local control may be beneficial to overall disease progression.

Oligo-recurrence encompasses recurrent disease limited in number and location so that loco-regional treatments convey disease control and survival benefits. Intra-hepatic recurrence can be managed with graft resection, but significant operative morbidity is expected. RFA and SBRRT are effective alternative strategies. In patients with more advanced hepatic disease, regional treatment with TACE or intra-arterial Yttrium-90 can be considered. For patients with extra-hepatic oligo-recurrence, loco-regional treatment can be considered if practical. Patients with more than one site of recurrence are not always contraindicated for curative treatments. Surgical resection is effective for patients with pulmonary oligo-recurrence, but adequate lung function is a prerequisite. SBRT is a non-invasive and effective modality that conveys local control to pulmonary and skeletal oligo-recurrences.

Recurrence of HCC after liver transplantation remains a deadly disease with rapid progression. However, with improved treatment modalities, long-term surviving patients are more frequently observed. More aggressive therapeutic strategies in selected patients with a limited disease burden appear to provide more favourable results than palliative measures. A multidisciplinary team is a comprehensive and coordinated approach to manage patients with post-transplant HCC recurrence.

REFERENCES

1 Yoo HY, Patt CH, Geschwind JF, Thuluvath PJ. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol 2003; 21: 4329-4335 [PMID: 14588446 DOI: 10.1200/JCO.2003.03.1137]

2 Zavaglia C, De Carlisi L, Alberghini S, Minella E, Belli LS, Slim AO, Airoldi A, Giacomoni A, Rondinana G, Tinelli C, Forti D, Pinzello G. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol 2005; 100: 2708-2716 [PMID: 16393224 DOI: 10.1111/j.1577-0249.2005.00289.x]

3 Regalia E, Fassati LR, Valente U, Pulvirenti A, Damilano I, Dardano G, Montalto F, Coppa J, Mazzaferrro V. Pattern and management of recurrent hepatocellular carcinoma after liver transplantation. J Hepatobiliary Pancreat Surg 1998; 5: 29-34 [PMID: 9683751]

4 Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, Krieger NR, Schwartz ME. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004; 10: 534-540 [PMID: 15048797 DOI: 10.1002/lt.20128]

5 Wienser RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology 2004; 127: S261-S267 [PMID: 15508092]

6 Yao FY, Bass NM, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: lessons from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy. Liver Transpl 2004; 10: 621-630 [PMID: 15108253 DOI: 10.1002/lt.20159]

7 Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007; 117: 1137-1146 [PMID: 17476343 DOI: 10.1172/JCI31405]

8 Altmann JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JJ, McMichael AJ, Davis MM. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274: 94-96 [PMID: 8810254]

9 Ruggiero RA, Bustuobad OD, Bonfil RD, Meiss RP, Pasqualini CD. “Concomitant immunity” in murine tumours of non-detectable immunogenicity. Br J Cancer 1985; 51: 37-48 [PMID: 2981538]

10 Yokoyama I, Carr B, Satoshi I, Iwasuki S, Starzl TE. Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation. Cancer 1991; 68: 2095-2100 [PMID: 1655200]

11 Hsio M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagmay M, Shimbo T, Suthanthiran M. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530-534 [PMID: 10028970 DOI: 10.1038/17401]

12 Maluccio M, Sharma V, Lagman M, Vyas S, Yang H, Li B, Suthanthiran M. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation 2003; 76: 597-602 [PMID: 12923450 DOI: 10.1097/01.TP.0000081399.75231.30]

13 Vivarelli M, Cucetti A, Pascaglia F, La Barba G, Bolondi L, Cavallari A, Pinna AD. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl 2005; 11: 497-503 [PMID: 15838913 DOI: 10.1002/lt.20391]

14 Vivarelli M, Cucetti A, La Barba G, Ravaiolli M, Del Gaudio M, Lauro A, Grazia GL, Pinna AD. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg 2008; 248: 857-862 [PMID: 18948815 DOI: 10.1097/SLA.0b013e3181986278]

15 Fairey S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006; 5: 671-688 [PMID: 16883305 DOI: 10.1038/nrd2062]

16 Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009; 9: 324-337 [PMID: 19390566 DOI: 10.1038/nri2546]

17 Bjorntsi MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4: 335-348 [PMID: 15122205 DOI: 10.1038/nrc1362]

18 Zhou Q, Lui VW, Yeo W. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncol 2011; 7: 1149-1167 [PMID: 21927228 DOI: 10.2217/fon.11.95]
Chen YT, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, Poon RT, Fan ST. 11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria: a prospective study. J Nucl Med 2013; 54: 192-200 [PMID: 23321459 DOI: 10.2967/jnumed.112.107516]

Cheung TT, Chan SC, Chan KH, Chok KS, Fung JY, Yan Chan AC, Sharr W, Yau T, Poon RT, Fan ST. 11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria: a systematic review and meta-analysis. Radiology; 2011; 258: 515-523 [PMID: 21069222 DOI: 10.1148/radiol.10100672]

Pecchi A, Besutti G, De Santis M, Del Giovane C, Nosseir S, Sellami DB, Chen LT. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 2014; 312: 57-67 [PMID: 25058218 DOI: 10.1001/jama.2014.17189]

Fischer L, Saliba F, Kaiser GM, De Carlis L, Metselaar HJ, De Simone P, Ducovx C, Nevens F, Fung JI, Dong G, Rauer B, Junge H, ZH204 Study Group. Three-year outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study. Transplantation 2015; 99: 1455-1462 [PMID: 25161607 DOI: 10.1097/TP.0000000000001055]

Jeng LB, Lee SG, Seo AS, Lee WC, Sub KS, Ioo DI, Uemoto S, Joh J, Yoshizumi T, Yang HR, Song GW, Lopez P, Kochuparambil J, Sips C, Kaneko S, Levy G. Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study. Am J Transplant 2018; 18: 1435-1446 [PMID: 29237235 DOI: 10.1111/ajt.14623]

Cholongitas E, Mamou C, Rodriguez-Castro KJ, Burra P. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int 2014; 27: 1039-1049 [PMID: 24493720 DOI: 10.1111/tis.12372]

Cheung TT, Ho CL, Lo CM, Chen S, Chan SC, Chok KS, Fung JY, Yan Chan AC, Sharr W, Yau T, Poon RT, Fan ST. 11C-acetate and 18-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria: surgeon’s perspective. J Nucl Med 2013; 54: 192-200 [PMID: 23321459 DOI: 10.2967/jnumed.112.107516]

Zaninetti M, Assenat E, Cattan S, Kang YK, Lim HY, Poon RT, Fan ST. 11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria: a systematic review and meta-analysis. Radiology; 2011; 258: 515-523 [PMID: 21069222 DOI: 10.1148/radiol.10100672]

JAMA 2014; 312: 57-67 [PMID: 25058218 DOI: 10.1001/jama.2014.17189]

Fischer L, Saliba F, Kaiser GM, De Carlis L, Metselaar HJ, De Simone P, Ducovx C, Nevens F, Fung JI, Dong G, Rauer B, Junge H, ZH204 Study Group. Three-year outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study. Transplantation 2015; 99: 1455-1462 [PMID: 25161607 DOI: 10.1097/TP.0000000000001055]

Jeng LB, Lee SG, Seo AS, Lee WC, Sub KS, Ioo DI, Uemoto S, Joh J, Yoshizumi T, Yang HR, Song GW, Lopez P, Kochuparambil J, Sips C, Kaneko S, Levy G. Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study. Am J Transplant 2018; 18: 1435-1446 [PMID: 29237235 DOI: 10.1111/ajt.14623]

Cholongitas E, Mamou C, Rodriguez-Castro KJ, Burra P. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int 2014; 27: 1039-1049 [PMID: 24493720 DOI: 10.1111/tis.12372]

Cheung TT, Ho CL, Lo CM, Chen S, Chan SC, Chok KS, Fung JY, Yan Chan AC, Sharr W, Yau T, Poon RT, Fan ST. 11C-acetate and 18-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria: surgeon’s perspective. J Nucl Med 2013; 54: 192-200 [PMID: 23321459 DOI: 10.2967/jnumed.112.107516]

Cheung TT, Chan SC, Ho CL, Chok KS, Chan KC, Sharr W, Ng KK, Poon RT, Lo CM, Fan ST. Can positron emission tomography with the dual tracers [11C]acetate and [18F]fluorodeoxyglucose predict microvascular invasion in hepatocellular carcinoma? Liver Transpl 2011; 17: 1218-1225 [PMID: 21688383 DOI: 10.1002/lt.22362]

Ho CL, Chen S, Cheng TK, Leung YL. PET/CT characteristics of isolated bone metastases in hepatocellular carcinoma. Radiology; 2011; 258: 515-523 [PMID: 21069222 DOI: 10.1148/radiol.10100672]

Pecchi A, Besutti G, De Santis M, Del Giovane C, Nosseir S, Tarantino G, Di Benedetto F, Torricelli P. Post-transplant hepatocellular carcinoma recurrence: Patterns and relation between vascularity and differentiation degree. World J Hepatol 2015; 7: 276-284 [PMID: 25729483 DOI: 10.4204/wjg.v7.i2.276]

Valdivieso A, Bastamante J, Gastaca M, Uriarte JG, Ventoso A, Ruiz P, Fernandez JR, Pijuan I, Testillano M, Suarez MJ, Montoro M, Ortiz de Urbina J. Management of hepatocellular carcinoma recurrence after liver transplantation. Transplant Proc 2010; 42: 660-662 [PMID: 20304217 DOI: 10.1016/j.transproceed.2010.02.014]

Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwarz B, Simantov R, Kelley S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5: 835-844 [PMID: 17016242 DOI: 10.1038/nrd2130]

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Grelle TF, Galte PR, Seitz JF, Borbath I, Huassinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoai0708857]

Mancuso A, Mazzola A, Cabibbo G, Perricone G, Enea M, Galvano A, Zavaglia C, Belli L, Camm C. Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis. Dig Liver Dis 2015; 47: 324-330 [PMID: 25641331 DOI: 10.1016/j.dld.2015.01.001]
Zavaglia C, Airoldi A, Mancuso A, Vangelı M, Vigano R, Cordone G, Gentiluomo M, Belli LS. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature. Eur J Gastroenterol Hepatol 2013; 25: 180-186 [PMID: 23040880 DOI: 10.1097/MEG.0b013e32835e550]

de'Angelis N, Landi F, Nencioni M, Palen A, Lahat E, Salloum C, Compagnon P, Lim C, Costentin C, Calderaro J, Luciani A, Feray C, Azoulay D. Role of Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation. Prog Transplant 2016; 26: 348-355 [PMID: 27555074 DOI: 10.1177/1524268316608033]

Piñero F, Marchiano S, Anders M. Sorafenib for Recurrent Hepatocellular Carcinoma after Liver Transplantation: A South American Experience

Yoon DH, Ryoo BY, Ryu MH, Lee SG, Hwang S, Suh DJ, Lee HC, Kim TW, Ahn CS, Kim KH, Moon DB, Kang YK. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Jpn J Clin Oncol 2010; 40: 768-773 [PMID: 20494947 DOI: 10.1093/jjco/hyp065]

Kim R, El-Gazzaz G, Tan A, Elson P, Byrne M, Chang YD, Ausco F. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation. Oncology 2010; 79: 62-66 [PMID: 21071991 DOI: 10.1159/000319548]

Vitale A, Boccagni P, Kertusha X, Zanus G, D’Amico F, Lodo E, Pastorelli D, Ramirez Morales R, Lombardi G, Senzolo M, Burra P, Cillo U. Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation? Transplant Proc 2012; 44: 1989-1991 [PMID: 22974889 DOI: 10.1016/j.proceed.2012.06.046]

Gomez-Martin C, Bustamante J, Castroagudín JF, Salcedo M, Garralda E, Testillano M, Herrero I, Matilla A, Sangro B. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl 2012; 18: 45-52 [PMID: 21923275 DOI: 10.1002/lt.22434]

Weimann A, Niederle JM, Koch S, Hoppe-Lotichius M, Heise M, Düber C, Schachmann M, Otto G, Galle PR, Wörns MA. Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. Dig Liver Dis 2012; 44: 432-437 [PMID: 22625328 DOI: 10.1016/j.dld.2011.12.009]

Sotiropoulos GC, Nowak KW, Fouzas I, Verdakakis S, Kykalos S, Klein CG, Paul A. Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation. Transplant Proc 2012; 44: 2754-2756 [PMID: 23416514 DOI: 10.1016/j.proceed.2012.09.022]

Newell P, Toffanin S, Villanueva A, Chiang DY, Mingué B, Cabellós S, Rivas S, Hoshia Y, Lim KH, Melgar-Lesmes P, Yu S, Peix J, Deniz K, Fiel MI, Thung S, Alsinet C, Thung T, Blazer BR, Rothstein DM, Sayegh MH, Najafian N. PDL1 is required for peripheral tolerance and protection from chronic allograft rejection. J Immunol 2007; 179: 5204-5210 [PMID: 17911605]

Zhang T, Fresnya S, Welty E, Sangrampurkar N, Rybak E, Zhou H, Cheng TX, Feng Q, Avon C, Lauris A, Whitmers M, Nagelin AM, O’Hara RM Jr, Azimzadeh AM. Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent manner. Am J Transplant 2011; 11: 1599-1609 [PMID: 21749640 DOI: 10.1111/j.1600-6143.2011.03624.x]

Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vuibel JM, Linette GP, Hogg D, Ottmann OE, Lebecq C, Peseluck Q, Clift I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723 [PMID: 20525592 DOI: 10.1056/NEJMoa1003663]

Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JF, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem Z, Harman K, Ibrahim F, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526 [PMID: 21639810 DOI: 10.1056/NEJMoa1046211]

De Toni EN, Gerbes AL. Tapering of Immunosuppression and Sustained Treatment With Nivolumab in a Liver Transplant Recipient. Gastroenterology 2017; 152: 1631-1633 [PMID: 28384452 DOI: 10.1053/j.gastro.2017.01.063]

Friend BD, Venick RS, McMardiv SD, Zhou X, Naini B, Wang H, Farmer DG, Busuttil RW, Federman N. Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma. Pediatr Blood Cancer 2017; 64 (12) [PMID: 28643391 DOI: 10.1002/pbc.26862]

Varkaris A, Lewis DW, Nugent FW. Preserved Liver Transplant After PD-1 Pathway Inhibitor for Hepatocellular Carcinoma. Am J Transplant 2017; 12: 1895-1896 [PMID: 29251567 DOI: 10.1038/ajt.2017.387]

DeleoNNT, SalomaMA, AqelBA. Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience. J Gastrointest Oncol. 2018; (suppl 4S) [DOI: 210372018.07.05]

Wang YC, Wu TJ, Wu TH, Lee CF, Chou HS, Chan KM, Lee WC. The risk factors to predict acute rejection in liver transplantation. Transplant Proc 2012; 44: 526-528 [PMID: 22410062 DOI: 10.1016/j.proceed.2012.01.041]

Liu M, Guo W, Zhang S. Cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation. Int J Surg Oncol (NY) 2017; 2: e49 [PMID: 29302641 DOI: 10.1097/JIO.0000000000000049]

Ranganath HA, Panella TJ. Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma. J Immunosur 2015; 18: 211 [PMID: 25962109 DOI: 10.1016/j.jil.2015.05.007]

Morales RE, Shoushtari AN, Walsh MM, Greiwal P, Lipson EJ, Carvajal RD. Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. J Immunother Cancer 2015; 3: 22 [PMID: 26082835 DOI: 10.1186/s40425-015-0066-0]

Kuo JC, Lilly LB, Hogg D. Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a
December 7, 2018

Weichselbaum RR. Oligometastases. 2010; Hering J, Saied A, Helton WS, Espat NJ. Küpper B, Tannapfel A, Katenkamp K, Thrum. 2010; Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, Jones JC, Strober S, Knox SJ. Characterization of Ko GY, Yoon HK, Sung KB. Tumor response to 2010; Yang DS, Park YJ, Yoon WS, Lee JA, Kim CY. Management of recurrent hepatocellular carcinoma 2016; 2015; 75 84 75 73 72 71 70 69 68 67 66 65 64 63 62 61 60 59 58 57 56 55 54 53 52 51 50 49 48 47 46 45 44 43 42 41 40 39 38 37 36 35 34 33 32 31 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1

Cancers

75
84
75
73
72
71
70
69
68
67
66
65
64
63
62
61
60
59
58
57
56
55
54
53
52
51
50
49
48
47
46
45
44
43
42
41
40
39
38
37
36
35
34
33
32
31
30
29
28
27
26
25
24
23
22
21
20
19
18
17
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1

WJC | www.wjgnet.com

5093

December 7, 2018 | Volume 24 | Issue 45

Figure 1: Schematic representation of the proposed mechanism for the therapeutic effect of radiotherapy on cancer cells. A: Tumor cells are exposed to ionizing radiation, which induces DNA damage, leading to cell death or apoptosis. B: Radiotherapy enhances the immune response, leading to the elimination of residual tumor cells. C: The immune system is activated by tumor antigens, leading to the development of an antitumor immune response. D: The antitumor immune response is further enhanced by the combination of radiotherapy and immunotherapy. E: The combination of radiotherapy and immunotherapy results in the eradication of residual tumor cells and the prevention of tumor recurrence. F: The combination of radiotherapy and immunotherapy is effective in patients with cancer, leading to improved survival rates and reduced rates of tumor recurrence. G: The combination of radiotherapy and immunotherapy is an exciting new approach for the treatment of cancer, with promising clinical outcomes.
transcatheter arterial chemoembolization in recurrent hepatocellular carcinoma after living donor liver transplantation. *Korean J Radiol* 2007; 8: 320-327 [PMID: 17673843 DOI: 10.3348/kjr.2007.8.4.320]

102 Zhou B, Shan H, Zhu KS, Jiang ZB, Guan SH, Meng XC, Zeng XC. Chemoembolization with lobaplatin mixed with iodized oil for unresectable recurrent hepatocellular carcinoma after orthotopic liver transplantation. *J Vasc Interv Radiol* 2010; 21: 333-338 [PMID: 20116286 DOI: 10.1016/j.jvir.2009.11.006]

103 Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, Sato KT, Wang E, Gupta R, Benson AB, Newman SB, Omary RA, Abecassis M, Kulik L. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. *Gastroenterology* 2010; 138: 52-64 [PMID: 19766639 DOI: 10.1053/j.gastro.2009.09.006]

104 Hwang S, Kim YH, Kim DK, Ahn CS, Moon DB, Kim KH, Ha TY, Song GW, Jung DH, Kim HR, Park GC, Namgoong JM, Yoon SY, Jung SW, Park SL, Lee SG. Resection of pulmonary metastases from hepatocellular carcinoma following liver transplantation. *World J Surg* 2012; 36: 1592-1602 [PMID: 22411088 DOI: 10.1007/s00268-012-1533-0]

105 Aoki M, Hatayama Y, Kawaguchi H, Hirose K, Sato M, Akimoto H, Miura H, Ono S, Takai Y. Stereotactic body radiotherapy for lung metastases as oligo-recurrence: a single institutional study. *J Radiat Res* 2016; 57: 55-61 [PMID: 26494115 DOI: 10.1093/jrr/rsv063]

106 Sahgal A, Larson DA, Chang EL. Stereotactic body radiosurgery for spinal metastases: a critical review. *Int J Radiat Oncol Biol Phys* 2008; 71: 652-665 [PMID: 18514775 DOI: 10.1016/j.ijrobp.2008.02.060]

107 Chang EL, Shiu AS, Mendel E, Mathews LA, Mahajan A, Allen PK, Weinberg JS, Brown BW, Wang XS, Woo SY, Cleeland C, Maor MH, Rhines LD. Phase IIb study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure. *J Neurosurg Spine* 2007; 7: 151-160 [PMID: 17688054 DOI: 10.3171/SPI-07/08/151]

108 Owen D, Laack NN, Mayo CS, Garces YI, Park SS, Bauer HJ, Nelson K, Miller RW, Brown PD, Olivier KR. Outcomes and toxicities of stereotactic body radiation therapy for non-spine bone oligometastases. *Pract Radiat Oncol* 2014; 4: e143-e149 [PMID: 24890360 DOI: 10.1016/j.prro.2013.05.006]

109 Ahmed KA, Stauder MC, Miller RC, Bauer HJ, Rose PS, Olivier KR, Brown PD, Brinkmann DH, Laack NN. Stereotactic body radiation therapy in spinal metastases. *Int J Radiat Oncol Biol Phys* 2012; 82: e803-e809 [PMID: 22330988 DOI: 10.1016/j.ijrobp.2011.11.036]

110 Lee E, Kim TG, Park HC, Yu Ji, Lim DH, Nam H, Lee H, Lee H. Clinical outcomes of stereotactic body radiotherapy for spinal metastases from hepatocellular carcinoma. *Radiat Oncol J* 2015; 33: 217-225 [PMID: 26484305 DOI: 10.3857/roj.2015.33.3.217]

111 Yoo GS, Park HC, Yu Ji, Lim DH, Cho WK, Lee E, Jung SH, Han Y, Kim ES, Lee SH, Eoh W, Park SJ, Chung SS, Lee CS, Lee JH. Stereotactic ablative body radiotherapy for spinal metastasis from hepatocellular carcinoma: its oncologic outcomes and risk of vertebral compression fracture. *Oncotarget* 2017; 8: 72860-72871 [PMID: 29069831 DOI: 10.18632/oncotarget.20529]
